BPN14770 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 206 | 脆弱Ｘ症候群 | 4 |
206. 脆弱Ｘ症候群
臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05367960 (ClinicalTrials.gov) | November 1, 2022 | 29/4/2022 | An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome | An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome | Fragile X Syndrome | Drug: Zatolmilast/ BPN14770 | Tetra Discovery Partners | NULL | Enrolling by invitation | 12 Years | 45 Years | Male | 300 | Phase 3 | United States |
| 2 | NCT05358886 (ClinicalTrials.gov) | November 1, 2022 | 27/4/2022 | A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome | Fragile X Syndrome | Drug: BPN14770/ zatolmilast;Drug: Placebo | Tetra Discovery Partners | NULL | Recruiting | 18 Years | 45 Years | Male | 150 | Phase 3 | United States |
| 3 | NCT05163808 (ClinicalTrials.gov) | March 29, 2022 | 15/12/2021 | A Randomized Study of BPN14770 in Male Adolescents (Aged 12 to < 18 Years) With Fragile X Syndrome | A Randomized, Double-blind, Placebo-controlled, Two-Part Study of High and Low Dose BPN14770 in Male Adolescents (Aged 12 to < 18 Years) With Fragile X Syndrome | Fragile X Syndrome | Drug: zatolmilast;Drug: Placebo | Tetra Discovery Partners | NULL | Recruiting | 12 Years | 18 Years | Male | 150 | Phase 2/Phase 3 | United States |
| 4 | NCT03569631 (ClinicalTrials.gov) | July 9, 2018 | 25/5/2018 | A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome | A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study of BPN14770 in Adult Males With Fragile X Syndrome | Fragile X Syndrome;FXS;Fra(X) Syndrome | Drug: BPN14770;Drug: Placebo | Tetra Discovery Partners | NULL | Completed | 18 Years | 45 Years | Male | 30 | Phase 2 | United States |